Resources

One North Quay, a 23-storey science, technology and innovation campus at Canary Wharf, has reached its full height.

This week, imphatec Ltd. has announced the close of an oversubscribed £1.5M seed round led by SynBioVen, with further participation from angel investors. imphatec is a British synthetic biology pharmaceutical company developing the first customisable-dose subcutaneous implant platform to treat chronic conditions.

Medannex Ltd (Edinburgh) today announced the presentation of updated clinical data from Module 1 of the ongoing ATTAINMENT study of MDX-124 at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid.

Quell Therapeutics announced that QEL-005, its CD19 B-cell activated Phenotype-Locked™ engineered nTreg therapy, has advanced to the second planned dose cohort in the CHILL Phase 1/2 clinical study.

Industry leaders gathered at Discovery Park on 14 October for The Lab of the Future & Green Chemistry Innovation, an event exploring pharmaceutical AI, automation and green chemistry, with speakers urging the industry to unite to share learnings and knowledge.

NRG Therapeutics announced a positron emission tomography (PET) imaging trial (NRG5051-102) to assess the biodistribution of its lead clinical asset NRG5051 has started.

Brainomix, announced the publication of new data from the REVISE PPF multicenter observational study demonstrating the potential of quantitative CT.

PIR International recently partnered with CellCentric in appointing Paolo Pucci as Independent Non-Executive Director.

IMU Biosciences has announced a new collaboration with UK Biobank to generate large-scale multi-omic immune profiling data.

Microbiotica announces the first close of a £36 million ($48 million) Series C financing.

Recursion announced a $200 million underwritten offering of common stock with leading healthcare and institutional investors.

Graham Hewson has been appointed as Chief Business Officer of the Royal Veterinary College (RVC) and Chief Executive Officer of the London Bioscience Innovation Centre (LBIC).

OMass Therapeutics announced an oversubscribed $310 million (£230 million) Series C financing round.

Brainomix, today announced a new partnership with the Pulmonary Fibrosis Foundation (PFF) to bring the voices of patients and caregivers into exploring how AI-powered imaging could support the care of people living with pulmonary fibrosis (PF) and other fibrotic interstitial lung diseases (ILD).

Engitix announced the appointment of Ryan Richardson to its Board of Directors as Independent Non-Executive Director (NED).

Discovery Park welcomed two climate-tech companies to its innovation campus

o2h Technology Launches Tech Kickstarter 5.0 to Support Early-Stage Startups

Alliance of CGT Manufacturing Partners (ACGMP) founding members aim to help cell and gene therapy developers find manufacturing partners across regions and modalities, with a shared focus on global patient access.

ELRIG announced the keynote speakers for Protein Sciences in Drug Discovery 2026.

Coulter Partners successfully led a search assignment for Valo Therapeutics Group to place Carlos de Sousa, M.D., MBA, as Chief Executive Officer.